In summary, intervention at the level of the ER subtypes or upstream at the level of ER-ligand availability holds promise for the effective treatment of molecular breast cancer subtypes in combination with kinase and immune checkpoint inhibitors. This evidence concerns the gene ESR1 and breast carcinoma.